Role of CXCR4 and MMP-9 Expressions with Regional Cervical Lymph Nodes Metastatic Status in Papillary Thyroid Carcinoma

Etty Hary Kusumastuti, Nurdhani Hi Djafar, Alphania Rahniayu

Abstract


Background: Papillary thyroid carcinoma (PTC) that has metastasized has a higher risk because of the poor prognosis, ranging from decreased quality of life of the patient to death. There is a need for markers that can understand the image of the tumor so that it can predict earlier the level of aggressiveness and the ability of tumor cells to metastasize. Tumor cells that proliferate excessively will cause CXCR4 expression. Activation of CXCR4 will increase MMP-9 via the MAPK/ ERK line. MMP-9 will degrade the extracellular matrix causing tumor cell metastasis. This study is aimed to analyze the correlation of CXCR4 and MMP-9 expressions with lymph node metastasis (LNM) in PTC.

Methods: This cross-sectional analytic observational study was conducted in 43 PTC samples taken from the Anatomical Pathology Laboratory of Dr. Soetomo Hospital from January 2011 to December 2018. The samples were divided into 2 groups based on the regional cervical LNM status. Immunohistochemical staining was used to assess the expression of CXCR4 and MMP-9. Spearman test was used to analyze the correlation of CXCR4 and MMP expression with cervical LNM status.

Results: The expression of CXCR4 and MMP-9 was higher in the papillary thyroid carcinoma group with cervical regional LNM (p = 0.007 and p = 0.030). There was a significant positive relationship between CXCR4 and MMP-9 expressions with regional LNM status with rs = 0.468 and p = 0.001 (p < 0.05).

Conclusions: Expression of CXCR4 and MMP-9 was proven to correlate with regional cervical LNM status in papillary thyroid carcinoma. Both can be used as predictive markers for metastasis in papillary thyroid carcinoma.


Keywords


CXCR4, lymph node metastasis, MMP-9, papillary thyroid carcinoma

References


Bu R, Siraj AK, Divya SP, et al. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in middle eastern papillary thyroid cancer. Int J Cancer. 2018;142(10):2028–39.

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2018;68(6):394–424.

Pusat Data dan Informasi Kementerian Kesehatan RI. Infodatin. Jakarta. 2015. https://pusdatin.kemkes.go.id.

Paulino TL, Holt E, Callender GG, et al. Management of Papillary Thyroid Cancer: An Overview for the Primary Care Physician. J Clin Outcomes Manag. 2014;21(5).

Jin WX, Jin YX, Ye DR, et al. Predictive factors of skip metastasis in papillary thyroid cancer. Med Sci Monit. 2018;3(24):2744-9.

Tallon P, Holt E, Callender G, et al. Management of papillary thyroid cancer: an overview for the primary care physician. J Clin Outcomes Manag. 2014;21(5):233-40.

Sun W, Lan X, Zhang H, et al. Risk factors for central lymph node metastasis in CN0 papillary thyroid carcinoma: a systematic review and meta-analysis. PloS ONE. 2015;10(10):e0139021.

Orbach GO. Risk stratification in differentiated thyroid cancer: An ongoing process. Rambam Maimonides Med J. 2016;7(1):e0003.

Gonza´ lez HE, Leiva A, Tobar H, et al. Altered chemokine receptor expression in papillary thyroid cancer. Thyroid. 2009;19(9):957-65.

Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927–31.

Lin Y, Ma Q, Li L, Wang H. The CXCL12/CXCR4 axis promotes migration, invasion and EMT in human papillary thyroid carcinoma B-CPAP cells via NF-κB signaling. Biochem Cell Biol. 2018;96(5):619-26.

Hua H, Li M, Luo T, et al. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011;68(23):3853–68.

Liao YX, Zhou CH, Zeng H, et al. The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review). Int J Mol Med. 2013;32(6):1239-46.

Luo D, Chen H, Li X, et al. Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma. Int J Oncol. 2017;51(4):1209-18.

Meng X, Hua T, Zhang Q, et al. Expression and clinical significance of matrix metalloproteinase 9 (MMP9) papillary thyroid carcinomas. Afr J Pharm Pharmacol. 2012;6(44):3075-9.

Torregrossa L, Giannini R, Borrelli N, et al. CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. Mod Pathol. 2011;25(1):46–55.

Dayer R, Babashah S, Jamshidi S, Sadeghizadeh M. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis in invasive breast carcinoma: A potent biomarker predicting lymph node metastasis. J Can Res Ther. 2018;4(2):345-50.

Cojoc M, Peitzsch C, Trautmann F, et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther. 2013;6:1347–61.

Hiller D, Chu QD. CXCR4 and axillary lymph nodes: review of potential biomarker for breast cancer metastasis. Int J Breast Cancer. 2011;(2011):1-6.

Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer. 2013;49(1):219–30.

Xu C, Zhao H, Chen H, and Yao Q. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015;9:4953–64.

Guo F, Wang Y, Liu J, et al. CXCL12/CXCR4 a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2015;35(7):816-26.

Liu X, Su C, Xu J, et al. Immunohistochemical analysis of matrix metalloproteinase‑9 predicts papillary thyroid carcinoma prognosis. Oncol Lett. 2018;17(2):2308-2316.

Hwang TL, Lee LY, Wang CC, et al. Claudin-4 expression is associated with tumor invasion, MMP-2 and MMP-9 expression in gastric cancer. Exp Ther Med. 2010;1(5):789-97.

Liabakk NB, Talbot I, Smith RA, et al. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996;56(1):190-6.

Parsons SL, Watson SA, Collins HM, et al. Gelatinase (MMP-2 and MMP-9) expression in gastrointestinal malignancy. Br J Cancer. 1998;78(11):1495-502.

Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013;48(3):222-72.

Conlon GA, Murray GI. Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 2019;247(5):629-40.

Liang H, Zhong Y, Luo Z, et al. Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis. The International Journal ff Biological Markers. 2010;25(1):38-45.

Hao L, Zhang C, Qiu Y, et al. Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett. 2007;253(1):34–42.

Zuo J, Wen M, Li S, et al. Overexpression of CXCR4 promotes invasion and migration of non small cell lung cancer via EGFR and MMP 9. Oncol Lett. 2017;14(6):7513–21.

Sticker TP and Kumar V. Neoplasia. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbins pathology basic of disease. 8th ed. Philadelphia: Saunders; 2010. p259-330.

Chinni SR, Sivalogan S, Dong Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate. 2006;66(1):32–48.


Full Text: PDF

DOI: 10.33371/ijoc.v15i2.771

Article Metrics

Abstract view : 78 times
PDF - 39 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.